Using National IVF Registries to Validate Clinical Outcomes Following IVF Covered by Health Insurance.

Objective: To evaluate in vitro fertilization (IVF) cycles covered by health insurance using a national commercial claims database and to validate key clinical events against national IVF registries.

Design: Retrospective cohort study SUBJECTS: US women aged 20-44 who underwent IVF from 2005 to 2020 in Optum's de-identified Clinformatics® Data Mart Database (CDM).

Exposure: Undergoing IVF MAIN OUTCOME MEASURES: IVF cycles and rates of pregnancies (inclusive of losses and terminations), live births, and live birth types (e.

Outcomes After Early Pregnancy Loss Management With Mifepristone Plus Misoprostol vs Misoprostol Alone.

Importance: Medication management of early pregnancy loss (EPL), or miscarriage, typically involves the administration of misoprostol with or without pretreatment with mifepristone. Combination treatment with mifepristone plus misoprostol is more effective than misoprostol alone but is underutilized in the US.

Objective: To describe differences in clinical outcomes after EPL management with mifepristone plus misoprostol vs misoprostol alone using commercial claims data.

Perinatal Psychotherapy Use and Costs Before and After Federally Mandated Health Insurance Coverage.

Importance: Insurance coverage affects health care access for many delivering women diagnosed with perinatal mood and anxiety disorders (PMADs). The Mental Health Parity and Addiction Equity Act (MHPAEA; passed in 2008) and the Patient Protection and Affordable Care Act (ACA; passed in 2010) aimed to improve health care access.

Objective: To assess associations between MHPAEA and ACA implementation and psychotherapy use and costs among delivering women overall and with PMADs.

Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.

Objective: Prostate cancer is the most common malignancy among men and following a positive prostate-specific antigen (PSA) screening test, patients may undergo more expensive diagnostic testing. However, testing-related out-of-pocket costs (OOPCs), which may preclude patients from completing the screening process, have not been previously quantified. OOPCs for follow-up diagnostic testing (i.